Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Musculoskeletal

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 5 · 71.4%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

All‐cause mortality · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

It is very uncertain whether infliximab changes mortality compared with rituximab (very low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
Peto OR 0.88 [0.05, 15.51]
Studies not reported
Very low

Remission · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

It is very uncertain whether infliximab changes remission compared with rituximab (very low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 0.44 [0.11, 1.81]
Studies not reported
Very low

Durable remission during additional · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

It is very uncertain whether infliximab changes durable remission during additional compared with rituximab (very low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 0.22 [0.03, 1.6]
Studies not reported
Very low

Flare‐ups or relapse (continuous) · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Any adverse event · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Severe AEs · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

It is very uncertain whether infliximab changes any severe AEs compared with rituximab (very low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 1.78 [0.2, 16.1]
Studies not reported
Very low

Withdrawals due to adverse events · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

It is very uncertain whether infliximab changes any withdrawals due to AEs compared with rituximab (very low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 2.7 [0.13, 58.24]
Studies not reported
Very low